A Nicotine Antagonist, Mecamylamine, Reduces Cue-Induced Cocaine Craving in Cocaine-Dependent Subjects Malcolm S

Total Page:16

File Type:pdf, Size:1020Kb

A Nicotine Antagonist, Mecamylamine, Reduces Cue-Induced Cocaine Craving in Cocaine-Dependent Subjects Malcolm S A Nicotine Antagonist, Mecamylamine, Reduces Cue-Induced Cocaine Craving in Cocaine-Dependent Subjects Malcolm S. Reid, Ph.D., Joanne D. Mickalian, M.S., Kevin L. Delucchi, Ph.D., and S. Paul Berger, M.D. We have previously shown that nicotine enhances cue- cue measures. Cue exposure also produced an increase in induced cocaine craving. In the present study, the effects of skin conductance and decrease in skin temperature. The a nicotine antagonist, mecamylamine, on cue-induced cue-induced increase in cocaine craving was reduced, cocaine craving were investigated. Twenty-three cocaine- while the cue-induced skin conductance and temperature dependent patients, all cigarette smokers, were randomly responses were unaffected, by mecamylamine. These assigned to mecamylamine (2.5 mg tablet) or placebo in a findings show that cue-induced cocaine craving is single-dose, placebo-controlled, crossover, double-blind attenuated by mecamylamine. Further study on the use study. Craving and anxiety were measured before and after of mecamylamine in relapse prevention programs cocaine cues with visual analog scales for desire to use are suggested. cocaine and mood. Skin conductance, skin temperature and [Neuropsychopharmacology 20:297–307, 1999] heart rate were recorded before and during cocaine cues. © 1999 American College of Neuropsychopharmacology. Following exposure to cocaine cues, all patients reported an Published by Elsevier Science Inc. increase in cocaine craving and anxiety relative to the pre- KEY WORDS: Cocaine; Craving; Mecamylamine; Nicotine; and cocaine paraphernalia handling (Ehrman et al. Addiction 1992; Reid et al. 1998). The cocaine cue procedure ap- pears to be contextually specific because opiate-related Over the past several years, numerous studies have cues are less effective whereas cues specific to the sub- demonstrated that environmental cues previously asso- ject’s mode of cocaine use are most effective (Ehrman et ciated with cocaine use will consistently induce cocaine al. 1992; O’Brien et al. 1990, 1992). Furthermore, cocaine craving in cocaine-dependent subjects (Ehrman et al. cue reactivity persists inpatients who have not used co- 1992; O’Brien et al. 1990; Berger et al. 1996; Reid et al. caine for several months (Rohsenow et al. 1991; O’Brien 1998). This behavior is readily elicited in a clinical labo- et al. 1990). In recent years, this model has been used to ratory setting by means of a standardized cocaine cue investigate medications for their ability to reduce cue- procedure involving both visual/audio presentation induced cocaine craving, and consequently, it has been proposed as a screening mechanism for identifying po- From the Psychiatry Services NYVAMC (MSR), New York Uni- tentially therapeutic compounds for the treatment of versity Medical Center, New York, New York; and Psychiatry Ser- vices SFVAMC (JDM, KLD, SPB), University of California, San cocaine addiction (Berger et al. 1996; Robbins et al. 1992; Francisco, California. Kranzler and Bauer 1992; Satel et al. 1995). Address correspondence to: Malcolm S. Reid, Psychiatry Ser- Studies investigating the pharmacological modula- vices, NYVAMC 116A, 423 East 23rd Street, New York, NY 10010. Received February 3, 1998; revised July 20, 1998; accepted July 22, tion of cue-induced cocaine craving have tested a wide 1998. variety of compounds. These include bromocriptine NEUROPSYCHOPHARMACOLOGY 1999–VOL. 20, NO. 3 © 1999 American College of Neuropsychopharmacology Published by Elsevier Science Inc. 0893-133X/99/$–see front matter 655 Avenue of the Americas, New York, NY 10010 PII S0893-133X(98)00076-1 298 M.S. Reid et al. NEUROPSYCHOPHARMACOLOGY 1999–VOL. 20, NO. 3 (Kranzler and Bauer 1992), amantadine (Robbins et al. done over the phone, followed by a screening interview 1992), haloperidol (Berger et al. 1996) and nicotine (Reid at the SFVAMC with a SAT trained psychology techni- et al. 1998), as well as tryptophan depletion, which re- cian with experience in cocaine abuse diagnosis and duces serotonin levels (Satel et al. 1995). Most of these treatment. Patients were included if they were: (1) studies found either a reduction (haloperidol, tryp- males or nonpregnant/nursing females, (2) 18–65 years tophan depletion) or no change (bromocriptine, aman- of age, (3) regular (10 cigarettes/day) cigarette smokers, tadine) in self-reported cocaine craving and have led to (4) “crack” cocaine was their drug of choice, (5) had the suggestion that dopamine may be involved in medi- smoked “crack” cocaine within the last 3 months and ating cocaine craving (Berger et al. 1996; Wickelgren (6) cocaine-dependent within the last 3 months accord- 1997). More recently, we found that nicotine produced ing to DSM-IV criteria from the Structural Clinical In- an increase in cue-induced cocaine craving (Reid et al. terview (SCID). Patient were excluded if they were: (1) 1998). This findings is consistent with previous investi- currently abusing opiates or in a methadone mainte- gations of cocaine–nicotine interactions. Thus, epidemi- nance program, (2) had undergone alcohol or drug ological studies have reported that cigarette smoking is detoxification within the last 30 days, (3) taking pre- significantly more prevalent in cocaine-dependent indi- scribed psychoactive medication, (4) taking prescribed viduals (Budney et al. 1993; Sees and Clark 1991), that antibiotics, (5) had coronary heart disease or high blood cocaine-dependent smokers reported an earlier age of pressure, or (6) had previously suffered from a serious onset and more frequent use of cocaine than cocaine- head injury (trauma) or stroke. The psychiatric status of dependent nonsmokers (Budney et al. 1993) and that all patients was initially evaluated by a Master’s degree smoking is predictive of the abuse of psychoactive level SAT psychologist. Those with erratic behavior drugs such as cocaine (Henningfield et al. 1990; U.S. De- were interviewed by an SAT psychiatrist, and if they partment of Health and Human Services 1988). Indeed, met criteria for an axis I psychiatric disorder (other than anecdotal reports by patients claim that smoking men- substance abuse), they were excluded from the study. tholated cigarettes prolongs the cocaine high and can Following the screening interview, written informed even substitute for cocaine during periods of abstinence consent was obtained, and all study participants under- (Sees and Clark 1991). Finally, animal studies have went an intake assessment including a demographic shown that subchronic pretreatment with nicotine in- questionnaire, the drug and alcohol sections of SCID for creases the subsequent acquisition and rate of cocaine DSM-IV (First et al. 1996), the Addiction Severity Index self-administration in rats (Horger et al. 1992). These (ASI) (McLellan et al. 1980), the Fagerström Nicotine studies indicate that nicotine could stimulate the use of Tolerance Questionnaire (Fagerström 1978) and the cocaine and possibly increase the risk of relapse in co- Profile of Mood States (POMS) (McNair et al. 1971), and caine-dependent individuals during rehabilitation. More- test dates for two separate sessions (at least 72 h apart) over, this suggests that a nicotine antagonist could reduce were scheduled. cue-induced cocaine craving and, consequently, could Descriptive data of the patient population derived be of therapeutic value in the treatment of cocaine addic- from the screening interview, ASI, POMS, and Fager- tion. Mecamylamine is a clinically available, centrally ström Nicotine Tolerance Questionnaire are shown in active nicotine antagonist with known therapeutic value Table 1. All patients abused cocaine by smoking in smoking cessation; it reduces relapse in cigarette “crack” cocaine, 14 of them had used within the last 30 smokers when combined with nicotine patch treatment days, 10 were currently in the SAT outpatient program, (Rose et al. 1994). Therefore, in the present study, we and all were current cigarette smokers. have investigated the effects of mecamylamine on cue- induced cocaine craving in cocaine-dependent “crack” Study Design: Methodological Considerations smokers. All patients were instructed to abstain from smoking from midnight before each test day. (Studies began at METHODS 9:30 A.M. and were completed by approximately 1:30 P.M.) Compliance was verified on each test day using a Participants carbon monoxide (CO) breath monitor (15 PPM cut-off This human study was approved by an independent, level). All patients were also instructed to abstain form University of California research council: Committee on cocaine use for at least 2 days before each test day, Human Research. Individuals were recruited from the which was verified with qualitative urine screens for transition group at the Substance Abuse Treatment cocaine (300 ng/ml cut-off). (SAT) clinic at the San Francisco Veterans Affairs Medi- Mecamylamine (2.5 mg tablet, Merck) or placebo cal Center (SFVAMC), as well as by word of mouth at (lactose tablet) were administered in gelcaps in a dou- other outpatient treatment clinics in the San Francisco ble-blind, randomized, counterbalanced design. All pa- metropolitan area. Initial contact and recruitment were tients served in all conditions resulting in a within-patient NEUROPSYCHOPHARMACOLOGY 1999–VOL. 20, NO. 3 Mecamylamine Reduces Conditioned Cocaine Craving 299 Table 1. Subject Demographics and Drug Use History Frequency Mean (SD) Demographics Race African American 19 Caucasian 4 Gender Male 20 Female 3 Age 40.6 (5.1) Income in last 30 days
Recommended publications
  • Synthesis and Characterization of in Vitro and in Vivo Profiles of Hydroxybupropion Analogues: Aids to Smoking Cessation
    Barrow Neurological Institute at St. Joseph's Hospital and Medical Center Barrow - St. Joseph's Scholarly Commons Neurobiology 6-24-2010 Synthesis And Characterization Of In Vitro And In Vivo Profiles Of Hydroxybupropion Analogues: Aids To Smoking Cessation Ronald J. Lukas Barrow Neurological Institute, [email protected] Ana Z. Muresan M. Imad Damaj Bruce E. Blough Xiaodong Huang See next page for additional authors Follow this and additional works at: https://scholar.barrowneuro.org/neurobiology Recommended Citation Lukas, Ronald J.; Muresan, Ana Z.; Damaj, M. Imad; Blough, Bruce E.; Huang, Xiaodong; Navarro, Hernan A.; Mascarella, S. Wayne; Eaton, J. Brek; Marxer-Miller, Syndia K.; and Carroll, F. Ivy, "Synthesis And Characterization Of In Vitro And In Vivo Profiles Of Hydroxybupropion Analogues: Aids To Smoking Cessation" (2010). Neurobiology. 280. https://scholar.barrowneuro.org/neurobiology/280 This Article is brought to you for free and open access by Barrow - St. Joseph's Scholarly Commons. It has been accepted for inclusion in Neurobiology by an authorized administrator of Barrow - St. Joseph's Scholarly Commons. For more information, please contact [email protected], [email protected]. Authors Ronald J. Lukas, Ana Z. Muresan, M. Imad Damaj, Bruce E. Blough, Xiaodong Huang, Hernan A. Navarro, S. Wayne Mascarella, J. Brek Eaton, Syndia K. Marxer-Miller, and F. Ivy Carroll This article is available at Barrow - St. Joseph's Scholarly Commons: https://scholar.barrowneuro.org/neurobiology/ 280 J. Med. Chem. 2010, 53, 4731–4748 4731 DOI: 10.1021/jm1003232 Synthesis and Characterization of in Vitro and in Vivo Profiles of Hydroxybupropion Analogues: Aids to Smoking Cessation Ronald J.
    [Show full text]
  • In Silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction
    In silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction Pathima Nusrath Hameed ORCID: 0000-0002-8118-9823 Submitted in total fulfilment of the requirements for the degree of Doctor of Philosophy Department of Mechanical Engineering THE UNIVERSITY OF MELBOURNE May 2018 Copyright © 2018 Pathima Nusrath Hameed All rights reserved. No part of the publication may be reproduced in any form by print, photoprint, microfilm or any other means without written permission from the author. Abstract Drug repositioning and drug-drug interaction (DDI) prediction are two fundamental ap- plications having a large impact on drug development and clinical care. Drug reposi- tioning aims to identify new uses for existing drugs. Moreover, understanding harmful DDIs is essential to enhance the effects of clinical care. Exploring both therapeutic uses and adverse effects of drugs or a pair of drugs have significant benefits in pharmacology. The use of computational methods to support drug repositioning and DDI prediction en- able improvements in the speed of drug development compared to in vivo and in vitro methods. This thesis investigates the consequences of employing a representative training sam- ple in achieving better performance for DDI classification. The Positive-Unlabeled Learn- ing method introduced in this thesis aims to employ representative positives as well as reliable negatives to train the binary classifier for inferring potential DDIs. Moreover, it explores the importance of a finer-grained similarity metric to represent the pairwise drug similarities. Drug repositioning can be approached by new indication detection. In this study, Anatomical Therapeutic Chemical (ATC) classification is used as the primary source to determine the indications/therapeutic uses of drugs for drug repositioning.
    [Show full text]
  • Cognitive, Behavioral, and Physiologic Responses John T
    Combined Nicotinic and Muscarinic Blockade in Elderly Normal Volunteers: Cognitive, Behavioral, and Physiologic Responses John T. Little, M.D., Douglas N. Johnson, Ph.D., Marcia Minichiello, M.A., Herb Weingartner, Ph.D., and Trey Sunderland, M.D. Establishing a pharmacologic model of the memory deficits scopolamine alone. Increased impairment was also seen for of Alzheimer’s disease could be an important tool in the mecamylamine 1 scopolamine condition as compared to understanding how memory fails. We examined the scopolamine alone in selected behavioral ratings. Pupil size combined effects of the muscarinic antagonist scopolamine increased when mecamylamine was added to scopolamine, and the nicotinic antagonist mecamylamine in eight normal while systolic blood pressure and pulse changed in elderly volunteers (age 61.9 6 8.3 yrs, SD). Each received concordance with ganglionic blockade. These data together four separate drug challenges (scopolamine (0.4 mg IV), with previous brain-imaging results suggest that this mecamylamine (0.2 mg/kg up to 15 mg PO), muscarinic–nicotinic drug combination may better model mecamylamine 1 scopolamine, and placebo). There was a Alzheimer’s disease than either drug alone. trend toward increased impairment in explicit memory for [Neuropsychopharmacology 19:60–69, 1998] the mecamylamine 1 scopolamine condition as compared to Published by Elsevier Science Inc. KEY WORDS: Scopolamine; Mecamylamine; Cognitive; al. 1985; Shimohama et al. 1986; Whitehouse and Au Geriatrics; Muscarinic antagonist; Nicotinic antagonist 1986; D’Amato et al. 1987; Zubenko et al. 1988), many cognitive dysfunction modeling studies have focused Given the limited animal models of Alzheimer’s disease on this system (Beatty et al.
    [Show full text]
  • Lubeluzole/Mecamylamine Hydrochloride 1331 Precautions Ing Treated
    Lubeluzole/Mecamylamine Hydrochloride 1331 Precautions ing treated. Mannitol infusion has also been used to de Manzanas; Pol.: Purisole SM; Port.: Purisole; Xarope de Macas Reinetas; Rus.: Rheogluman (Реоглюман); Spain: Salcemetic†; Salmagne; Switz.: Mannitol is contra-indicated in patients with pulmo- prevent acute renal failure during cardiovascular and Cital†. nary congestion or pulmonary oedema, intracranial other types of surgery, or after trauma. bleeding (except during craniotomy), heart failure (in To reduce raised intracranial or intra-ocular pres- patients with diminished cardiac reserve, expansion of sure mannitol may be given by intravenous infusion as Mebutamate (BAN, USAN, rINN) the extracellular fluid may lead to fulminating heart a 15 to 25% solution in a dose of 0.25 to 2 g/kg over 30 Mébutamate; Mebutamato; Mebutamatum; W-583. 2-sec-Butyl- failure), and in patients with renal failure unless a test to 60 minutes. Rebound increases in intracranial or 2-methyltrimethylene dicarbamate. dose has produced a diuretic response (if urine flow is intra-ocular pressure may occur but are less frequent Мебутамат inadequate, expansion of the extracellular fluid may than with urea. C10H20N2O4 = 232.3. lead to acute water intoxication). During transurethral prostatic resection a 2.5 to 5% CAS — 64-55-1. Mannitol should not be given with whole blood. ATC — N05BC04. solution of mannitol has been used for irrigating the ATC Vet — QN05BC04. All patients given mannitol should be carefully ob- bladder. served for signs of fluid and electrolyte imbalance and Ciguatera poisoning. Ciguatera poisoning occurs throughout O O renal function should be monitored. the Caribbean and Indopacific as a result of the consumption of certain fish contaminated with ciguatoxin; it is increasingly seen Pharmacokinetics in Europe, in travellers returning from these areas, or as a result H2NO O NH2 Only small amounts of mannitol are absorbed from the of eating imported fish.
    [Show full text]
  • III IIHIIII US005574052A United States Patent (19) 11 Patent Number: 5,574,052 Rose Et Al
    III IIHIIII US005574052A United States Patent (19) 11 Patent Number: 5,574,052 Rose et al. 45) Date of Patent: *Nov. 12, 1996 54) AGONIST-ANTAGONIST COMBINATION TO Nicotine Self-Administration..., H. M. Hanson, et al., Ch. REDUCE THE USE OF NICOTINE AND 7 Norman A. Krasnegor, NIDA Research Monograph 23, OTHER DRUGS Jan. 1979. Influencing Cigarette Smoking ..., I. P. Stolerman, et. al., (75 Inventors: Jed E. Rose, Venice; Edward D. Psychopharmacologia (Berl.) 28–247-249 (1973). Levin, Los Angeles, both of Calif. Effects of Mecamylamine On Human Cigarette Smoking . , Nemeth-Coslett, et al., Pharmacology (1986) (73) Assignee: Robert J. Schaap, Los Angeles, Calif.; 88:420-425. a part interest Rapid Phsiologic Effects of Nicotine ..., J. Henningfield, et al., U.S. Dept. of Health and Human Services, 259-265. * Notice: The term of this patent shall not extend Could Nicotine Antagonists Be Used..., by I. P. Stolerman, beyond the expiration date of Pat. No. Br, Jr. of Addiction (1986) 81, 47-53. 5,316,759. Mecamylamine Pretreatment . , C. S. Pomerleau, et. al., Pharmacology (1987) 91:391-393. (21) Appl. No.: 235,454 Clinical Evaluation of Mecamylamine..., F. S. Tennant, Jr., et al., NIDA Research Monograph, Feb. 9 (1984). 239–246. (22 Filed: Apr. 29, 1994 Withdrawl From Nicotine Dependence ..., F. S. Tennant, Jr., et al., NIDA Research Monograph, 55 (1985). Related U.S. Application Data Double-Blind Comparison . , F. S. Tennant, Jr., UCLA, Los Angeles, California. 63) Continuation of Ser. No. 54,144, Apr. 30, 1993, which is a Involvement of Cholinergic Nicotine-like Receptors . continuation of Ser. No. 855,868, Mar.
    [Show full text]
  • MECAMYLAMINE Hydrochloride Tablets, USP, 2.5 Mg
    MECAMYLAMINE HYDROCHLORIDE- mecamylamine hydrochloride tablet Nexgen Pharma, Inc. ---------- MECAMYLAMINE Hydrochloride Tablets, USP, 2.5 mg DESCRIPTION Mecamylamine HCl is a potent, oral antihypertension agent and ganglion blocker, and is a secondary amine. It is N,2,3,3-tetramethyl-bicyclo [2.2.1] heptan- 2 -amine hydrochloride. Its empirical formula is C11H21N • HCl and its structural formula is: It is a white, odorless, or practically odorless, crystalline powder, is highly stable, soluble in water and has a molecular weight of 203.75. Mecamylamine HCl is supplied as tablets for oral use, each containing 2.5 mg mecamylamine HCl. Inactive ingredients are calcium phosphate, D&C Yellow 10, FD&C Yellow 6, lactose, magnesium stearate, cornstarch, and talc. CLINICAL PHARMACOLOGY Mecamylamine HCl reduces blood pressure in both normotensive and hypertensive individuals. It has a gradual onset of action (1/2 to 2 hours) and a long-lasting effect (usually 6 to 12 hours or more). A small oral dosage often produces a smooth and predictable reduction of blood pressure. Although this antihypertensive effect is predominantly orthostatic, the supine blood pressure is also significantly reduced. Pharmacokinetics and Metabolism Mecamylamine HCl is almost completely absorbed from the gastrointestinal tract, resulting in consistent lowering of blood pressure in most patients with hypertensive cardiovascular disease. Mecamylamine HCl is excreted slowly in the urine in the unchanged form. The rate of its renal elimination is influenced markedly by urinary pH. Alkalinization of the urine reduces, and acidification promotes, renal excretion of mecamylamine. Mecamylamine HCl crosses the blood-brain and placental barriers. INDICATIONS AND USAGE For the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension.
    [Show full text]
  • Nicotinic Mechanisms Modulate Ethanol Withdrawal and Modify Time Course and Symptoms Severity of Simultaneous Withdrawal from Alcohol and Nicotine
    Neuropsychopharmacology (2015) 40, 2327–2336 © 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org Nicotinic Mechanisms Modulate Ethanol Withdrawal and Modify Time Course and Symptoms Severity of Simultaneous Withdrawal from Alcohol and Nicotine 1,2 3 ,1,2,4 Erika Perez , Natalia Quijano-Cardé and Mariella De Biasi* 1 2 Department of Neuroscience, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of 3 4 Neuroscience, Baylor College of Medicine, Houston, TX, USA; University of Puerto Rico at Mayagüez, Mayagüez, Puerto Rico; Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA Alcohol and nicotine are among the top causes of preventable death in the United States. Unfortunately, people who are dependent on alcohol are more likely to smoke than individuals in the general population. Similarly, smokers are more likely to abuse alcohol. Alcohol and nicotine codependence affects health in many ways and leads to poorer treatment outcomes in subjects who want to quit. This study examined the interaction of alcohol and nicotine during withdrawal and compared abstinence symptoms during withdrawal from one of the two drugs only vs both. Our results indicate that simultaneous withdrawal from alcohol and nicotine produces physical symptoms that are more severe and last longer than those experienced during withdrawal from one of the two drugs alone. In animals experiencing withdrawal after chronic ethanol treatment, acute nicotine exposure was sufficient to prevent abstinence symptoms. Similarly, symptoms were prevented when alcohol was injected acutely in mice undergoing nicotine withdrawal. These experiments provide evidence for the involvement of the nicotinic cholinergic system in alcohol withdrawal.
    [Show full text]
  • Discriminative Stimulus Effects of Mecamylamine and Nicotine In
    Pharmacology, Biochemistry and Behavior 179 (2019) 27–33 Contents lists available at ScienceDirect Pharmacology, Biochemistry and Behavior journal homepage: www.elsevier.com/locate/pharmbiochembeh Discriminative stimulus effects of mecamylamine and nicotine in rhesus monkeys: Central and peripheral mechanisms T ⁎ Colin S. Cunningham, Megan J. Moerke, Lance R. McMahon Department of Pharmacodynamics, The University of Florida, Gainesville, FL, USA ABSTRACT Mecamylamine is a non-competitive nicotinic acetylcholine receptor (nAChR) antagonist that has been prescribed for hypertension and as an off-label smoking cessation aid. Here, we examined pharmacological mechanisms underlying the interoceptive effects (i.e., discriminative stimulus effects) of mecamylamine (5.6 mg/ kg s.c.) and compared the effects of nAChR antagonists in this discrimination assay to their capacity to block a nicotine discriminative stimulus (1.78 mg/kg s.c.) in rhesus monkeys. Central (pempidine) and peripherally restricted nAChR antagonists (pentolinium and chlorisondamine) dose-dependently substituted for the me- camylamine discriminative stimulus in the following rank order potency (pentolinium > pempidine > chlorisondamine > mecamylamine). In contrast, at equi- effective doses based on substitution for mecamylamine, only mecamylamine antagonized the discriminative stimulus effects of nicotine, i.e., pentolinium, chlor- isondamine, and pempidine did not. NMDA receptor antagonists produced dose-dependent substitution for mecamylamine with the following rank order potency (MK-801 > phencyclidine > ketamine). In contrast, behaviorally active doses of smoking cessation aids including nAChR agonists (nicotine, varenicline, and cytisine), the smoking cessation aid and antidepressant bupropion, and the benzodiazepine midazolam did not substitute for the discriminative stimulus effects of mecamylamine. These data suggest that peripheral nAChRs and NMDA receptors may contribute to the interoceptive stimulus effects produced by mecamylamine.
    [Show full text]
  • Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys
    1521-0103/366/2/397–409$35.00 https://doi.org/10.1124/jpet.118.248070 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:397–409, August 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys Sarah L. Withey,1 Michelle R. Doyle,1,2 Jack Bergman, and Rajeev I. Desai Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, Belmont, Massachusetts Received January 27, 2018; accepted May 17, 2018 ABSTRACT Evidence suggests that the a4b2, but not the a7, subtype of the except for lobeline, the nicotinic agonists produced either full nicotinic acetylcholine receptor (nAChR) plays a key role in [(1)-epibatidine, (2)-epibatidine, and nicotine] or partial (vare- Downloaded from mediating the behavioral effects of nicotine and related drugs. nicline, cytisine, anabaseine, and isoarecolone) substitution for However, the importance of other nAChR subtypes remains (1)-epibatidine. In interaction studies with antagonists differing unclear. The present studies were conducted to examine the in selectivity, (1)-epibatidine discrimination was substan- involvement of nAChR subtypes by determining the effects of tively antagonized by mecamylamine, slightly attenuated selected nicotinic agonists and antagonists in squirrel monkeys by hexamethonium (peripherally restricted) or dihydro- b a either 1) responding for food reinforcement or 2) discriminating the -erythroidine, and not altered by methyllycaconitine ( 7 jpet.aspetjournals.org nicotinic agonist (1)-epibatidine (0.001 mg/kg) from vehicle. In selective). Varenicline and cytisine enhanced (1)-epibati- food-reinforcement studies, nicotine, (1)-epibatidine, varenicline dine’s discriminative-stimulus effects.
    [Show full text]
  • Analysis of Mecamylamine Stereoisomers on Human Nicotinic Receptor Subtypes
    0022-3565/01/2972-646–656$3.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 297, No. 2 Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics 3541/898983 JPET 297:646–656, 2001 Printed in U.S.A. Analysis of Mecamylamine Stereoisomers on Human Nicotinic Receptor Subtypes ROGER L. PAPKE, PAUL R. SANBERG, and R. DOUGLAS SHYTLE Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida (R.L.P.); and Departments of Neurosurgery and Psychiatry and the Neuroscience Program, University of South Florida College of Medicine, Tampa, Florida (P.R.S., D.S.) Received November 9, 2000; accepted for publication January 23, 2001 This paper is available online at http://jpet.aspetjournals.org ABSTRACT Downloaded from Because mecamylamine, a nicotinic receptor antagonist, is hibited by higher micromolar concentrations. Mecamylamine used so often in nicotine research and because mecamylamine inhibition of neuronal nAChR was noncompetitive and voltage may have important therapeutic properties clinically, it is im- dependent. Although there was little difference between S-(ϩ)- portant to fully explore and understand its pharmacology. In the mecamylamine and R-(Ϫ)-mecamylamine in terms of 50% in- present study, the efficacy and potency of mecamylamine and hibition concentration values for a given receptor subtype, its stereoisomers were evaluated as inhibitors of human ␣3␤4, there appeared to be significant differences in the off-rates for ␣3␤2, ␣7, and ␣4␤2 nicotinic acetylcholine receptors (nAChRs), the mecamylamine isomers from the receptors. Specifically, jpet.aspetjournals.org as well as mouse adult type muscle nAChRs and rat N-methyl- S-(ϩ)-mecamylamine appeared to dissociate more slowly from D-aspartate (NMDA) receptors expressed in Xenopus oocytes.
    [Show full text]
  • Biological Processes Underlying Co-Use of Alcohol and Nicotine
    BIOLOGICAL MECHANISMS BIOLOGICAL PROCESSES UNDERLYING The fact that alcohol and tobacco are readily and legally CO-USE OF ALCOHOL AND NICOTINE: available likely contributes to their co-use. Over the past two NEURONAL MECHANISMS, CROSS­ decades, however, it has become increasingly clear that bio­ TOLERANCE, AND GENETIC FACTORS logical factors also contribute to the concurrent use of alco­ hol and nicotine—that is, certain common physiological mechanisms may account for people’s liability to use both Douglas Funk, Ph.D.; Peter W. Marinelli, Ph.D.; alcohol and nicotine. Several such mechanisms have been and Anh D. Lê, Ph.D. suggested. For example, both alcohol and nicotine may enhance a person’s motivation to also consume the other drug by act­ Alcohol and nicotine are two of the oldest and most ing on a common target in the brain that is responsible for commonly used recreational drugs, and many people use the reinforcing effects of both drugs. Alternatively, cross-toler­ both of them together. Although their ready availability ance between the two drugs may reduce the drugs’ aversive likely contributes to the strong correlation between alcohol effects and motivate people to use more of the drugs in order and nicotine use, several lines of evidence suggest that to achieve the same rewarding effects. (The concept of cross- biological factors play a role as well. For example, both tolerance will be explained in more detail in the section “Toler­ alcohol and nicotine act on a brain system called the ance and Cross-Tolerance.”) The study of this possible mech­ mesolimbic dopamine system, which mediates the rewarding and reinforcing properties of both drugs.
    [Show full text]
  • Impact on Patient Satisfaction with Methadone
    INFLUENCING FACTORS ON METHADONE PHARMACOLOGY: IMPACT ON PATIENT SATISFACTION WITH METHADONE MAINTENANCE TREATMENT by Alexander Khaled Elkader A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Graduate Department of Pharmaceutical Sciences University of Toronto © Copyright by Alexander Khaled Elkader (2009) i Influencing Factors on Methadone Pharmacology: Impact on Patient Satisfaction with Methadone Maintenance Treatment. Alexander Khaled Elkader Doctor of Philosophy Department of Pharmaceutical Sciences University of Toronto 2009 Abstract: The methadone maintenance treatment population suffers from high rates of comorbid psychiatric and substance use disorders. Despite a more than 40-year treatment history, not all patients are satisfied with methadone treatment and more than half of the patients complain of significant inter-dose withdrawal at least some of the time. The objectives of this research were to investigate the pharmacological response to methadone under the influence of comorbid major depressive disorder and smoking; and to identify factors other than physical withdrawal symptoms that can differentiate patients based on their complaints of dissatisfaction with treatment. In Study 1, seven depressed methadone maintenance patients experienced more opioid withdrawal symptomatology over a 24- hour methadone-dosing interval than 10 nondepressed methadone patients. Depression severity was significantly correlated with trough opioid withdrawal severity. This suggests that depression or depressive symptoms are related to reported opioid withdrawal. In Study 2, many factors other than physical opioid withdrawal symptoms were able to differentiate patients who were satisfied with treatment (holders, n=25), partially satisfied with treatment (partial holders, n=35), and not satisfied with treatment (nonholders, n=30). Results suggested that these patient satisfaction groups cluster differently depending on physical opioid withdrawal, mood, psychological distress, and ii personality.
    [Show full text]